CARBOPLATIN IN PREVIOUSLY TREATED MULTIPLE-MYELOMA - A CANCER AND LEUKEMIA GROUP-B PHASE-II TRIAL

被引：2

作者：

OMURA, GA

PERRI, RT

PETERSON, B

SCHIFFER, CA

机构：

[1] UNIV ALABAMA,BIRMINGHAM,AL 35294

[2] UNIV MINNESOTA,MINNEAPOLIS,MN 55455

[3] DUKE UNIV,DURHAM,NC 27706

[4] UNIV MARYLAND,BALTIMORE,MD 21201

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1994年 / 17卷 / 03期

关键词：

CARBOPLATIN; CHEMOTHERAPY; TOXICITY;

D O I：

10.1097/00000421-199406000-00003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Carboplatin 400 Mg/M2 per month was evaluated as a single agent in 15 patients with multiple myeloma who had had one prior chemotherapy regimen. All but three were judged to have had some degree of refractoriness to prior therapy. Hematologic toxicity was frequent and sometimes severe. There were no responses. Further evaluation of standard-dose single-agent carboplatin in refractory myeloma does not appear warranted.

引用

页码：196 / 198

页数：3

共 50 条

[1] CARBOPLATIN IN MALIGNANT MESOTHELIOMA - A PHASE-II STUDY OF THE CANCER AND LEUKEMIA GROUP-B
VOGELZANG, NJ
GOUTSOU, M
CORSON, JM
SUZUKI, Y
GRAZIANO, S
AISNER, J
COOPER, MR
COUGHLIN, KM
GREEN, MR
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (03) : 239 - 242
[2] PHASE-II TRIAL OF CARBOPLATIN IN ADVANCED BREAST-CARCINOMA - A CANCER AND LEUKEMIA GROUP-B STUDY
BOOTH, BW
WEISS, RB
KORZUN, AH
WOOD, WC
CAREY, RW
PANASCI, LC
CANCER TREATMENT REPORTS, 1985, 69 (7-8): : 919 - 920
[3] PHASE-II STUDY OF CARBOPLATIN (CBDCA) IN REFRACTORY MULTIPLE-MYELOMA
BARLOGIE, B
CROWLEY, J
SALMON, SE
BONNET, J
WEICK, JK
HAYDEN, K
INVESTIGATIONAL NEW DRUGS, 1994, 12 (01) : 53 - 55
[4] PENTOSTATIN IN CHRONIC LYMPHOCYTIC-LEUKEMIA - A PHASE-II TRIAL OF CANCER AND LEUKEMIA GROUP-B
DILLMAN, RO
MICK, R
MCINTYRE, OR
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (04) : 433 - 438
[5] PHASE-II TRIAL OF AMSACRINE IN PATIENTS WITH HEPATOMA - A CANCER AND LEUKEMIA GROUP-B STUDY
AMREIN, PC
RICHARDS, F
COLEMAN, M
POULIN, RF
HOLLAND, JF
WEINBERG, V
PERRY, M
CANCER TREATMENT REPORTS, 1984, 68 (06): : 923 - 924
[6] PHASE-II TRIAL OF SPIROGERMANIUM IN BREAST ADENOCARCINOMA - A CANCER AND LEUKEMIA GROUP-B STUDY
BUDMAN, DR
GINSBERG, S
PERRY, M
WEINBERG, V
SCHEIN, P
HANSON, J
COLEMAN, M
WOOD, W
CANCER TREATMENT REPORTS, 1982, 66 (08): : 1667 - 1668
[7] PHASE-I-II TRIAL OF HIGH-DOSE MELPHALAN IN PREVIOUSLY UNTREATED STAGE-III MULTIPLE-MYELOMA - CANCER AND LEUKEMIA GROUP-B STUDY 8512
CASE, DC
COLEMAN, M
GOTTLIEB, A
MCCARROLL, K
CANCER INVESTIGATION, 1992, 10 (01) : 11 - 17
[8] PHASE-II TRIAL OF AMSACRINE IN PATIENTS WITH MULTIPLE-MYELOMA
GREIPP, PR
COLEMAN, M
ANDERSON, K
MCINTYRE, OR
MEDICAL AND PEDIATRIC ONCOLOGY, 1989, 17 (01): : 76 - 78
[9] PHASE-II TRIAL OF IFOSFAMIDE AND MESNA IN PREVIOUSLY TREATED PATIENTS WITH NON-HODGKINS-LYMPHOMA - CANCER AND LEUKEMIA GROUP-B STUDY-8552
CASE, DC
ANDERSON, J
ERVIN, TJ
GOTTLIEB, A
HEMATOLOGICAL ONCOLOGY, 1991, 9 (4-5) : 189 - 196
[10] PHASE-II TRIAL OF IFOSFAMIDE AND MESNA IN PREVIOUSLY TREATED PATIENTS WITH NON-HODGKINS LYMPHOMA - CANCER AND LEUKEMIA GROUP-B STUDY-8552
CASE, DC
ANDERSON, J
ERVIN, TJ
GOTTLIEB, A
MEDICAL AND PEDIATRIC ONCOLOGY, 1988, 16 (03): : 182 - 186

← 1 2 3 4 5 →